Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: The role of postheparin lipases in the metabolism of high-density lipoprotein subfractions

This publication has 25 references indexed in Scilit:

• Reduced HDL2 levels in myocardial infarction patients without risk factors for atherosclerosis
  Atherosclerosis, 1987
• Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
  New England Journal of Medicine, 1987
• Measurement of total HDL, HDL2 and HDL3 by dextran sulfate—MgCl2 precipitation technique in human serum
  Clinica Chimica Acta; International Journal of Clinical Chemistry, 1986
• Lipid Metabolism in 31 Chinese Patients on three 2–L Exchanges of CAPD
  Peritoneal Dialysis International, 1986
• Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients
  Kidney International, 1984
• The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
  JAMA, 1984
• Lipid abnormalities in uremia, dialysis, and transplantation
  Kidney International, 1981
• ARE APOLIPOPROTEINS BETTER DISCRIMINATORS THAN LIPIDS FOR ATHEROSCLEROSIS?
  The Lancet, 1979
• Quantitation of apolipoprotein A-I of human plasma high density lipoprotein
  Metabolism, 1976
• PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
  The Lancet, 1975